The complement system, a crucial component of the innate immune response, has been implicated in various inflammatory conditions. Pegcetacoplan, a complement inhibitor, was initially approved in the U.S. in 2021 for paroxysmal nocturnal hemoglobinuria and later for age-related macular degeneration. Recent clinical trials have now revealed its potential in treating C3 glomerulopathy (C3G), an ultra-rare kidney condition affecting approximately 5,000 Americans, predominantly children and young adults.
Published in the New England Journal of Medicine, the trial led by Dr. Carla Nester demonstrated a remarkable 68% reduction in urinary protein levels among participants, with up to 67% achieving complete remission. This contrasts sharply with traditional treatments that only mitigate inflammation rather than address the underlying dysfunction within the complement system.
The Phase III trial, conducted across 122 centers globally, resulted in pegcetacoplan’s FDA approval as the first therapy for patients aged 12 and older with C3G and related conditions. This advancement underscores a significant shift in treatment paradigms, moving from broad anti-inflammatory approaches to targeted therapies that precisely inhibit complement activation, promising a transformative impact on patient outcomes.
Start your 7-day trial and see what the database can do →
